Chiron Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Chiron Investment Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,389	Closed	-$1.46M	–	117
2024 Q3	$1.46M	Sell	1,389 -604	-30%	-$672K	0.51%	45
2024 Q2	$2.09M	Buy	1,993 +1,147	+136%	+$1.11M	0.82%	32
2024 Q1	$814K	Buy	846 +231	+38%	+$220K	0.35%	39
2023 Q4	$540K	Buy	+615	New	+$506K	0.21%	42
2023 Q3	–	Sell	-540	Closed	-$388K	–	130
2023 Q2	$388K	Sell	540 -2,798	-84%	-$2.16M	0.11%	81
2023 Q1	$2.74M	Buy	3,338 +3,289	+6,712%	+$2.48M	0.49%	41
2022 Q4	$35.4K	Buy	+49	New	+$36.2K	0.01%	124
2020 Q4	$11.3M	Buy	23,425 +8,969	+62%	+$4.84M	1.57%	31
2020 Q3	$8.09M	Buy	+14,456	New	+$8.77M	1.5%	39

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Chiron Investment Management's REGN Position: Q4 2024 in Review

Chiron Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 1,389 shares — an estimated $1.46M sold.

Chiron Investment Management first reported a position in REGN in Q3 2020 and held it in 9 quarters. The position peaked at $11.3M in Q4 2020. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Chiron Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Chiron Investment Management sold 1,389 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $1.46M.
Chiron Investment Management first reported a position in Regeneron Pharmaceuticals in Q3 2020 and held it in 9 quarters.
Chiron Investment Management's Regeneron Pharmaceuticals position peaked at $11.3M in Q4 2020.
1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Chiron Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.